Prostate cancer is the most common noncutaneous prostate cancer. Research has revealed several distinct malignancy and the second leading cause of cancer mechanisms of castration-resistant disease that may deaths among men in the United States. It is a critical converge in patients with disease progression on public health problem and remains incurable in the ADT. Many approaches are currently being evaluated metastatic setting with mortality that usually occurs as to improve the treatment of this condition and these a result of castration-resistant disease. fndings have identifed several potential targets for Since Huggins and Hodges¿ report of the dra- therapeutic intervention. These include drugs that are matic clinical effects of suppressing serum testos- more active or less toxic chemotherapy agents; drugs terone levels in men with advanced prostate cancer that induce androgen deprivation; drugs that target in 1941, hormone therapy (also called androgen the androgen receptor and/or androgen synthesis; deprivation therapy [ADT]) has become widely drugs that target specifc pathways, including ang- accepted as the mainstay of therapy for the treat- genesis and tyrosine kinase inhibitors, endothelin ment of advanced prostate cancer. ADT combined antagonists and matrix metalloproteinase inhibitors; with radiation therapy is a standard of care in the and immunologic approaches. Many of these agents treatment of men with locally advanced prostate seem promising and the rationale and effcacy of cancer on the basis of evidence that shows improved these emerging therapies remain to be validated in survival. The role of ADT in the management of future clinical trials.

Provides a comprehensive guide to the spectrum of emerging pharmacologic agents

Section One Hormone TherapyChapter 1 Cell Biology of Prostate Cancer and Molecular TargetsMartin E. Gleave, Michael E. Cox, Yuzhuo WangChapter 2 Luteinizing Hormone-Releasing Hormone (Lh-Rh) and its Agnostic, Antagonistic and Targeted Cytotoxic Analogs in Prostate CancerAndrew V. Schally and Norman L. BlockChapter 3 Nuclear Receptor Coregulators: Promising Therapeutic Targets for the Treatment of Prostate CancerHannelore V. Heemers and Donald J. TindallChapter 4 Androgens and Prostate CancerDouglas K. Price and Ann W. HsingChapter 5 Androgen Receptor Biology in Prostate CancerEdward P. GelmannChapter 6 Androgen Receptor AntagonistsHoward C. Shen, Mary-Ellen Taplin, Steven P. BalkChapter 7 5 alpha Reductase Inhibitors in Prostate CancerZoran CuligChapter 8 Adrenolytic Therapies in Castration Resistant Prostate CancerTerence W. Friedlander and Charles J. RyanChapter 9 Androgen Deprivation TherapyNima SharifiChapter 10 Pharmacogenetics of the Androgen Metabolic PathwayFrancine Zanchetta Coehlo Marques and Juergen ReichardtSection Two ChemotherapyChapter 11 MitoxantronePatricia Halterman, Nicholas J. Vogelzang, Alireza Farabishahadel, Oscar B. Goodman, Jr.Chapter 12 DocetaxelCourtney K. Phillips and Daniel P. PetrylakChapter 13 Beyond Docetaxel: Emerging Agents in the Treatment of Advanced Prostate CancerJonathan RosenbergChapter 14 Platinum Agents in Prostate CancerAshley Brick, Junyang Niu, Jiaoti Huang, William K. OhChapter 15 Clinical Pharmacology and Pharmacogenetics of Chemotherapy in Prostate CancerTristan M. Sissung and William D. FiggChapter 16 Microtubule Targeting AgentsAntonio Tito Fojo and David E. AdelbergSection Three AngiogenesisChapter 17 Principles of Antiangiogenic TherapyCindy H. Chau and William D. FiggChapter 18 Bevacizumab in Advanced Prostate CancerAymen A. Elfiky and William Kevin KellyChapter 19 Thalidomide and AnalogsErin R. Gardner, Giuseppe Di Lorenzo, and William D. FiggChapter 20 Investigational Angiogenesis InhibitorsJeanny B. Aragon-Ching, William Dahut, MDChapter 21 Pharmacogenetics of AngiogenesisGuido Bocci, Giuseppe Pasqualetti, Antonello Di Paolo, Francesco Crea, Mario Del Tacca, Romano DanesiSection Four Bone MetastasisChapter 22 Pathophysiology of Prostate Cancer Bone MetastasisEvan T. Keller and Christopher L. HallChapter 23 RadiopharmaceuticalsOliver Sartor and Damerla R. VenugopalChapter 24 Bisphosphonates for Prevention and Treatment of Bone MetastasesPhilip J. Saylor and Matthew R. SmithChapter 25 Endothelin Receptors as Therapeutic Targets in Castrate Resistant Prostate CancerJoel B. NelsonChapter 26 Calcitriol and Vitamin D AnalogsAna R. Jensen, Russell Z. Szmulewitz, Tomasz M. Beer, Edwin M. PosadasChapter 27 Cancer Immunology, Immunotherapeutics and Vaccine ApproachesRavi A. Madan, James L. Gulley, Jackie Celestin, Philip M. Arlen, Jeffrey SchlomChapter 28 Sipuleucel-T (APC8015): Active Cellular Immunotherapy for Advanced Metastatic Castrate-Resistant Prostate CancerCelestia S. Higano and Mark W. FrohlichChapter 29 GM-CSF Genes Transduced Prostate Cancer Vaccines: GVAXLalit R. Patel and Jonathan W. SimonsChapter 30 CTLA-4 Blockade for Prostate Cancer TreatmentAndrea L. Harzstark and Lawrence FongSection Five ¿ PreventionChapter 31 Prostate Cancer Chemoprevention StrategiesHoward L. Parnes, Margaret G. House, Joseph A. TangreaChapter 32 Diet and Prostate Cancer Incidence, Recurrence, and Progression RiskJune M. Chan and Erin L. RichmanChapter 33 Inflammation as a Target in Prostate CancerMarshall Scott Lucia, James R. Lambert, Elizabeth A. Platz, Angelo M. De MarzoSection Six Drug DevelopmentChapter 34 Challenges for the Development of New Agents in Prostate CancerAjjai S. Alva, Deborah A. Bradley, Maha HussainChapter 35 FDA Approval of Prostate Cancer